Log in

Relevant bibliographies by topics / Bevacizumab, Perfusion CT, angiogenesis, brain tumor

Contents

Journal articles
Dissertations / Theses
Book chapters

Academic literature on the topic 'Bevacizumab, Perfusion CT, angiogenesis, brain tumor'

Author: Grafiati

Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bevacizumab, Perfusion CT, angiogenesis, brain tumor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bevacizumab, Perfusion CT, angiogenesis, brain tumor"

1

Wang, Yuan, Brian P. Hobbs, and Chaan S. Ng. "CT Perfusion Characteristics Identify Metastatic Sites in Liver." BioMed Research International 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/120749.

Full text

Abstract:

Tissue perfusion plays a critical role in oncology because growth and migration of cancerous cells require proliferation of new blood vessels through the process of tumor angiogenesis. Computed tomography (CT) perfusion is an emerging functional imaging modality that measures tissue perfusion through dynamic CT scanning following intravenous administration of contrast medium. This noninvasive technique provides a quantitative basis for assessing tumor angiogenesis. CT perfusion has been utilized on a variety of organs including lung, prostate, liver, and brain, with promising results in cancer

APA, Harvard, Vancouver, ISO, and other styles

2

Kang, Liqing, Yunting Zhang, and Shimei Sun. "Experimental study on angiogenesis in rabbit VX2 brain tumor using perfusion CT." Chinese-German Journal of Clinical Oncology 5, no. 6 (2006): 431–35. http://dx.doi.org/10.1007/s10330-006-0522-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Eoli, Marica, Anna Luisa Di Stefano, Domenico Aquino, et al. "Tumor perfusion during bevacizumab and irinotecan in recurrent glioblastoma: A multimodal approach." Journal of Clinical Oncology 31, no. 15_suppl (2013): 2074. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.2074.

Full text

Abstract:

2074 Background: Angiogenesis is a requirement for progression of glioblastoma (GBM) and vascular endothelial growth factor (VEGF) is a mediator of neo-angiogenesis in this tumor. Bevacizumab (Bev), an antibody directed to VEGF, was recently used to treat GBM. However in vivo modifications induced by treatment are still not clearly understood. Aim of this study is to analyze tumor changes induced by Irinotecan (Ir) and Bev, using two different methodologies: relative CBV variation (rCBV) and Difference Perfusion Maps (DPMs). Methods: 42 recurrent GBM patients underwent Bev (10 mg/kg) and Ir (1

APA, Harvard, Vancouver, ISO, and other styles

4

Popa, Andra M., Kelly Valla, Latha Radhakrishnan, Sandra Cuellar, and J. Lee Villano. "Bevacizumab-Induced Oral Mucositis in Background of Cutaneous Plaque-Type Psoriasis." Annals of Pharmacotherapy 46, no. 11 (2012): e32-e32. http://dx.doi.org/10.1345/aph.1r350.

Full text

Abstract:

OBJECTIVE: To report the serial development of oral mucositis following infusion of bevacizumab in a young woman with a malignant brain tumor and history of cutaneous psoriasis. CASE SUMMARY: A 29-year-old woman with a history of active cutaneous psoriasis and a malignant glioneuronal tumor was treated with bevacizumab for 2.5 years. With each infusion of bevacizumab, she developed oral mucositis within 36 hours. She received temozolomide as part of concurrent therapy with radiation and as maintenance therapy; it was discontinued after continuous therapy for 1.5 years. Bevacizumab 10 mg/kg was

APA, Harvard, Vancouver, ISO, and other styles

5

Narayana, A., S. Chheang, E. Knopp, et al. "Comparing cerebral blood volume and vascular permeability measurements with tumor volume measurements following anti-angiogenesis therapy in recurrent gliomas." Journal of Clinical Oncology 25, no. 18_suppl (2007): 2030. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.2030.

Full text

Abstract:

2030 Background: Dynamic susceptibility contrast-enhanced MRI (DSC MRI) is emerging as an important adjunctive biomarker to assess the effectiveness of anti-angiogenic therapies in the treatment of brain tumors. The purpose of our study is to compare changes in relative cerebral blood volume (rCBV) and in perfusion-permeability index (KTrans) with those of tumor volume measurements (T1c, T2/Flair) in predicting tumor therapeutic response in recurrent high-grade gliomas treated with bevacizumab, an anti-VEGF monoclonal antibody. Methods: 11 patients were treated with one to four cycles of bevac

APA, Harvard, Vancouver, ISO, and other styles

6

Huang, Abel Po-Hao, Jui-Chang Tsai, Lu-Ting Kuo, et al. "Clinical application of perfusion computed tomography in neurosurgery." Journal of Neurosurgery 120, no. 2 (2014): 473–88. http://dx.doi.org/10.3171/2013.10.jns13103.

Full text

Abstract:

Object Currently, perfusion CT (PCT) is a valuable imaging technique that has been successfully applied to the clinical management of patients with ischemic stroke and aneurysmal subarachnoid hemorrhage (SAH). However, recent literature and the authors' experience have shown that PCT has many more important clinical applications in a variety of neurosurgical conditions. Therefore, the authors share their experiences of its application in various diseases of the cerebrovascular, neurotraumatology, and neurooncology fields and review the pertinent literature regarding expanding PCT applications

APA, Harvard, Vancouver, ISO, and other styles

7

Zheng, Shuhua, and Wensi Tao. "Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme." Cancers 13, no. 5 (2021): 1013. http://dx.doi.org/10.3390/cancers13051013.

Full text

Abstract:

Glioblastoma multiforme (GBM) is the most common and devastating type of primary brain tumor, with a median survival time of only 15 months. Having a clinically applicable genetic biomarker would lead to a paradigm shift in precise diagnosis, personalized therapeutic decisions, and prognostic prediction for GBM. Radiogenomic profiling connecting radiological imaging features with molecular alterations will offer a noninvasive method for genomic studies of GBM. To this end, we analyzed over 3800 glioma and GBM cases across four independent datasets. The Chinese Glioma Genome Atlas (CGGA) and Th

APA, Harvard, Vancouver, ISO, and other styles

8

Faivre, S. J., E. Raymond, J. Douillard, et al. "Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 3546. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.3546.

Full text

Abstract:

3546 Background: VEGFRs and PDGFRs play key roles in the proliferation of HCC and tumor angiogenesis. Sunitinib malate (SU) is an oral, multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, RET and FLT3. This study reports the results of the first European/Asian, open-label, single-agent SU phase II study in pts with unresectable HCC. Methods: Key eligibility criteria include histologically confirmed measurable HCC; ECOG PS =1; Child-Pugh (CP)-A/-B; adequate organ function; and no brain metastases, ascites, or prior liver transplant. Pts receive SU at 50 mg/d for 4 wks every 6 wks (4

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Bevacizumab, Perfusion CT, angiogenesis, brain tumor"

1

OUSMANE, YEO DOGNIMIN. "COMPUTED TOMOGRAPHY FOR EVALUATION OF TUMOUR ANGIOGENESIS: THE CONTRIBUTION OF ADVANCED QUANTITATIVES PARAMETERS." Doctoral thesis, 2020. http://hdl.handle.net/2158/1196419.

Full text

Abstract:

Abstract: Objective. The aim of this study was to know if quantitative parameters of perfusion CT could predict the response of bevacizumab therapy on patients with brain cancer based on the RECIST.1.1 guidelines Material and methods. This study included 18 patients (11 men and 7 women; mean age, 47,11 years) with brain neoplasm who were undergoing bevacizumab treatment. by comparing baseline studies with the best response achieved after completion of bevacizumab treatment and chemotherapy, patients were divided into two groups according to RECIST (version 1.1) guidelines as follows; resp

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Bevacizumab, Perfusion CT, angiogenesis, brain tumor"

1

Jain, Rajan. "Brain Tumor Angiogenesis and Glioma Grading: Role of Tumor Blood Volume and Permeability Estimates Using Perfusion CT." In Tumors of the Central Nervous System, Volume 2. Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-0618-7_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!